Related Experiment Video
Updated: Aug 15, 2026
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
A chronobiologic approach to the pharmacotherapy of hypertension and angina
1Department of Pharmacy Practice, University of Utah, Salt Lake City 84112-5820, USA. mmunger@deans.pharm.utah.edu
Insights
Chronotherapy, the timing of medication, aligns drug delivery with the body's natural rhythms to potentially improve outcomes for cardiovascular disease. Further clinical trials are needed to confirm long-term benefits over traditional treatments.
Area of Science:
- Cardiovascular chronobiology and chronotherapeutics.
Background:
- Cardiovascular disease exhibits well-established circadian rhythms, with peak incidence of events like myocardial infarction and stroke in the early morning.
- Heart rate and blood pressure naturally increase in the morning and decrease at night.
Purpose of the Study:
- To review the chronobiology of hypertension and coronary artery disease.
- To explore the application of chronotherapeutics in the treatment and prevention of cardiovascular disease.
Main Methods:
- A MEDLINE search (1990-2000) identified clinical trials and review articles on chronotherapy and cardiovascular disease.
- Focus was on published studies examining circadian variation in pharmacotherapy for cardiovascular conditions.
Main Results:
- Circadian rhythms significantly influence cardiovascular events, with morning surges in heart rate, blood pressure, and event incidence.
- Chronotherapeutics aims to optimize drug efficacy by timing administration with these biological rhythms.
- New chronotherapeutic formulations are being developed for targeted drug delivery during high-risk morning hours.
Conclusions:
- The application of chronotherapeutics in cardiovascular disease shows promise for improving outcomes.
- Long-term clinical trials are essential to validate the advantages of chronotherapy over traditional treatment approaches.
Objective:
To review the chronobiology of hypertension and coronary artery disease and the application of chronotherapeutics to their treatment and prevention.
Data Sources:
Clinical trials and review articles (English-language) on the topic of chronotherapy and cardiovascular disease were identified via a MEDLINE search from 1990 to March 2000, using the search terms chronotherapy, circadian rhythm, cardiovascular disease, hypertension, and angina.
Data Extraction:
Search and evaluation focused on published clinical trials and review articles of circadian variation associated with pharmacotherapy for cardiovascular disease.
Data Synthesis:
The existence of circadian rhythm in cardiovascular disease is well established. Heart rate and blood pressure peak during the morning hours and reach a nadir at bedtime. The incidence of myocardial infarction, stroke, sudden cardiac death, and myocardial ischemia also increases during the early-morning hours. Based on these relationships, researchers have begun to apply the science of chronotherapeutics, or timing of drug effect with biologic need, to improve cardiovascular outcomes. This includes administering traditional agents at specific times throughout the day and developing new agents--chronotherapeutic formulations with special release mechanisms--targeted at inducing the greatest effect during the morning surges. Chronotherapeutic agents are specifically designed to provide peak plasma concentrations during the early-morning hours, when effect appears most needed; lowest concentrations occur at night, when heart rate and blood pressure are lowest and, consequently, cardiovascular events are least likely to occur.
Conclusions:
Whether chronotherapy of cardiovascular disease offers an advantage in long-term outcomes over traditional therapy must be studied in clinical trials.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications